{
    "clinical_study": {
        "@rank": "45344", 
        "arm_group": [
            {
                "arm_group_label": "Arm Label: Month 0, 1 and 3 Schedule", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Day 1, 8, and 30 Schedule", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will investigate a clostridium difficile vaccine in healthy adults aged 50 to 85\n      years, who will each receive 3 doses of vaccine. Subjects will receive their vaccine doses\n      at either months 0, 1, and 3 or days 1, 8, and 30. Subjects will be divided into 2 age\n      groups (50-64 and 65-85 years of age). The study will assess how safe and tolerable the\n      vaccine is, and also look at subjects' immune response to the vaccine."
        }, 
        "brief_title": "A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Clostridium Difficile", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female adults aged 50 to 85 years at enrollment\n\n        Exclusion Criteria:\n\n          -  Proven or suspected prior episode of Clostridium difficile associated diarrhea.\n\n          -  Unstable chronic medical condition or disease requiring significant change in therapy\n             or hospitalization for worsening disease within 8 weeks before receipt of study\n             vaccine.\n\n          -  Any contraindication to vaccination or vaccine components, including previous\n             anaphylactic reaction to any vaccine or vaccine-related components"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "344", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052726", 
            "org_study_id": "B5091002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm Label: Month 0, 1 and 3 Schedule", 
                "description": "C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.", 
                "intervention_name": "C. difficile vaccine with adjuvant", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Arm Label: Month 0, 1 and 3 Schedule", 
                "description": "Placebo administered at Month 0, 1, and 3.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Day 1, 8, and 30 Schedule", 
                "description": "C. difficile vaccine with adjuvant administered at day 1, 8, 30.", 
                "intervention_name": "C. difficile vaccine with adjuvant", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Day 1, 8, and 30 Schedule", 
                "description": "Placebo administered at Day 1, 8, and 30.", 
                "intervention_name": "placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5091002&StudyName=A%20Study%20To%20Investigate%20A%20Clostridium%20Difficile%20Vaccine%20In%20Healthy%20Adults%20Aged%2050%20To%2085%20Years%2C%20Who%20Will%20Each%20Receive%203%20Doses%20Of%2"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66212"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cary", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27518"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27612"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77081"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Annandale", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22003"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sudbury", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "P3E 1H5"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M9W 4L6"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mont-Royal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3P 3P1"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H4N 3C5"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sherbrooke", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J1H 1Z1"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G1W4R4"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Placebo-Controlled, Randomized, Observer-Blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of An Adjuvanted Clostridium Difficile Vaccine Administered As A 3-Dose Regimen In Healthy Adults Aged 50 To 85 Years", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Proportion of subjects reporting local reactions (pain, erythema, and induration) and their severity, as self reported on e-diaries.", 
                "safety_issue": "Yes", 
                "time_frame": "7 days after vaccination"
            }, 
            {
                "measure": "Proportion of subjects reporting systemic events (fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, and new or worsening joint pain) and their severity, as self reported on e-diaries.", 
                "safety_issue": "Yes", 
                "time_frame": "7 days after vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052726"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects in each vaccine group with neutralizing antibody levels (in Neut units/mL) greater than or equal to specified threshold(s).", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months post-dose 3"
            }, 
            {
                "measure": "Proportion of subjects in each vaccine group with neutralizing antibody levels, expressed as geometric mean concentrations (GMCs) (in Neut units/mL).", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months post-dose 3"
            }, 
            {
                "measure": "Proportion of subjects in each vaccine group with a greater than or equal to 4 and higher fold-rises in  neutralizing antibody levels (in Neut units/mL).", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months post-dose 3"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}